Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees

Meryem Grabski, Jon Waldron, Tom P. Freeman, Margriet van Laar, H. Valerie Curran

Research output: Contribution to journal › Article › peer-review

7 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences